Mark A Wade
Overview
Explore the profile of Mark A Wade including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
121
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rodriguez-Barucg Q, Garcia A, Garcia-Merino B, Akinmola T, Okotie-Eboh T, Francis T, et al.
Environ Pollut
. 2024 Sep;
362:124952.
PMID: 39277126
This study investigates the effects of environmentally-relevant concentrations of fluoxetine (FLX, commercial name: Prozac) on wound healing. Pollution of water systems with pharmaceutical and personal care products, including antidepressants such...
2.
Haigh T, Beattie H, Wade M, England J, Kuvshinov D, Karsai L, et al.
Int J Mol Sci
. 2024 Jan;
25(1).
PMID: 38203243
Small extracellular vesicles (sEVs) contain microRNAs (miRNAs) which have potential to act as disease-specific biomarkers. The current study uses an established method to maintain human thyroid tissue ex vivo on...
3.
Barry A, Samuel S, Hosni I, Moursi A, Feugere L, Sennett C, et al.
Lab Chip
. 2023 May;
23(11):2664-2682.
PMID: 37191188
Arginine methylation is a post-translational modification that consists of the transfer of one or two methyl (CH) groups to arginine residues in proteins. Several types of arginine methylation occur, namely...
4.
Bilton L, Warren C, Humphries R, Kalsi S, Waters E, Francis T, et al.
Cancers (Basel)
. 2022 Jul;
14(14).
PMID: 35884550
Chromobox 2 (CBX2) is a chromatin-binding component of polycomb repressive complex 1, which causes gene silencing. CBX2 expression is elevated in triple-negative breast cancer (TNBC), for which there are few...
5.
Jones D, Wilson L, Thomas H, Gaughan L, Wade M
Cancers (Basel)
. 2019 Aug;
11(8).
PMID: 31390833
Many estrogen receptor (ER)-positive breast cancers develop resistance to endocrine therapy but retain canonical receptor signalling in the presence of selective ER antagonists. Numerous co-regulatory proteins, including enzymes that modulate...
6.
Wade M, May F, Onel K, Allan J
Mol Cell Oncol
. 2016 Jun;
3(1):e1010950.
PMID: 27308527
The MYC (v-myc avian myelocytomatosis viral oncogene homolog; c-MYC) locus on chromosome 8q is susceptible to high-level amplification following exposure of human breast cells to ionizing radiation, and c-MYC amplification...
7.
Middleton F, Patterson M, Elstob C, Fordham S, Herriott A, Wade M, et al.
Oncotarget
. 2015 Oct;
6(32):32396-409.
PMID: 26486089
ATR is an attractive target in cancer therapy because it signals replication stress and DNA lesions for repair and to S/G2 checkpoints. Cancer-specific defects in the DNA damage response (DDR)...
8.
Wade M, Jones D, Wilson L, Stockley J, Coffey K, Robson C, et al.
Nucleic Acids Res
. 2014 Dec;
43(1):196-207.
PMID: 25488809
Endocrine therapy has successfully been used to treat estrogen receptor (ER)-positive breast cancer, but this invariably fails with cancers becoming refractory to treatment. Emerging evidence has suggested that fluctuations in...